SHS_492314 PAGJ CTGT 16028

A Phase 2 Study to Assess the Safety and Efficacy of TGR‐1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K‐Delta Inhibitor Therapy

The purpose of this study is to determine the progression free survival of TGR-1202 in patients who were intolerant to prior BTK and/or PI3K-delta inhibitors.
Phase II
NCT02742090
Cancer
Hematologic
John Pagel, M.D.
TG Therapeutics, Inc.
Neil Bailey
  • Swedish Medical Center